Embecta said its patch pump would require additions to be commercially competitive, and plans to use the funds saved to pay ...
CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the ...
Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.
A jury found that competitor EOFlow and former executives misappropriated trade secrets for Insulet’s Omnipod insulin pumps.
Embecta reports fourth quarter earnings beating estimates, discontinues insulin patch program, and announces restructuring ...
Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...
The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...
Get up to 30% off detailed market research reports-for a limited time only! The insulin patch pumps market size is expected to see rapid growth in the next few years. It will grow to $2.16 billion ...
Insulin pump maker Insulet won $452 million in its trade secret case against Korean rival EOFlow, the company announced on ...
Embecta Corp. has notified the state that it intends to terminate 118 employees that work out of its facility at 200 Bulfinch ...
Embecta Corp.'s Q4 results showed significant net income and EPS growth. Embecta also announced a restructuring plan. See why ...
The Massachusetts district court awarded Insulet a total of $452 million, including $170 million in compensation plus $282 ...